SynthesisJournal of cutaneous medicine and surgery
Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis.
Synthesis in Journal of cutaneous medicine and surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The adverse effects of oral niacin/nicotinamide - an overview of reviews.Eye (London, England) · 2025Pooled it
- Clinical and Dermoscopic Comparison of the Efficacy and Safety of 5% Fluorouracil Topical Cream and 1% Niacinamide Topical Gel in the Treatment of Actinic Keratosis: A Randomized Controlled Trial.Journal of cosmetic dermatology · 2025Trial
- Skin Cancer Prevention and Antiaging: Role of Nicotinamide.International journal of molecular sciences · 2026Review
- Nicotinamide for Skin Cancer Chemoprevention: The Jury Was Out and Still is.American journal of clinical dermatology · 2026Review
- Oral Nicotinamide for the Secondary Prevention of Cutaneous Squamous Cell Carcinoma and Other Keratinocyte Carcinomas: A Systematic Review.Journal of skin cancer · 2026Review
- Nicotinamide for Skin Cancer Chemoprevention.JAMA dermatology · 2025Article
- Risk of Major Adverse Cardiovascular Events Following Nicotinamide Exposure.JAMA dermatology · 2025Article
- Nicotinamide: A Multifaceted Molecule in Skin Health and Beyond.Medicina (Kaunas, Lithuania) · 2025Review
- Personalized Photoprotection: Expert Consensus and Recommendations From a Delphi Study Among Dermatologists.Photodermatology, photoimmunology & photomedicine · 2025Article
- Update on skin cancer prevention modalities and screening protocols in solid organ transplant recipients: a scoping review.Archives of dermatological research · 2024Article
- No Increased Risk of Major Adverse Cardiovascular Events following Nicotinamide Exposure.medRxiv : the preprint server for health sciences · 2024Article
- Epidemiology and Risk Factors of Actinic Keratosis. What is New for The Management for Sun-Damaged Skin.Dermatology practical & conceptual · 2024Review
- Review
- Unconventional Remedies for Squamous Cell Carcinoma: A Journey into Alternative Treatments.Current pharmaceutical biotechnology · 2024Review
- Article
- Systemic Photoprotection in Melanoma and Non-Melanoma Skin Cancer.Biomolecules · 2023Review
- Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.International journal of molecular sciences · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOral nicotinamide is recommended in individuals with a field of cancerization or with ≥1 previous cutaneous squamous cell carcinoma (cSCC).
objectiveTo evaluate the effect of nicotinamide in prevention of skin cancers.
methodsWe conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the effect of nicotinamide. We used Medline, EMBASE, CENTRAL, and Web of Science databases from their inception to October 2020 to search the following concepts: "nicotinamide"; "randomized controlled trial" (validated filters). Two independent reviewers screened titles and abstracts for intervention and study design before searching full texts for eligibility criteria. To be eligible, ≥1 outcome had to be covered. We used a standardized collection grid to complete data extraction in duplicate. The primary outcome was skin cancers (all types). Secondary outcomes were basal cell carcinomas (BCCs); cSCCs; actinic keratoses; melanomas; digestive, cutaneous, and biochemical adverse effects (AEs). Subgroup analyses were planned
resultsWe screened 4730 citations and found 29 trials (3039 patients) meeting inclusion criteria. Nicotinamide was associated with a significant reduction in skin cancers compared to control (rate ratio 0.50 (95% CI, 0.29-0.85;
conclusionOral nicotinamide should be considered in healthy patients or organ transplant recipients with history of skin cancer (GRADE: weak recommendation; moderate-quality evidence), in particular of BCC and cSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.